Fesoterodine, 5-[(1R,5R)-3-Azabicyclo[3.1.0]Hexan-1-Yl]-3-Methyl-1,2,4-Oxadiazole

2 trials 1 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

0 Completed trials

1 Sponsors

9 Countries

Phase II

Phase II: 2

Indications tested

Dementia of the Alzheimer's type with delusions 2

Sponsors using this IMP

Maplight Therapeutics Inc. 2

All trials

2 total

An Open-Label Study of ML-007C-MA in Adults with Alzheimer’s Disease Psychosis Pending

2025-521757-16-00 Phase II 9 countries Maplight Therapeutics Inc.
A Study of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis Recruiting

2024-519820-26-00 Phase II 9 countries Maplight Therapeutics Inc.

Showing 1–2 of 2 trials

← All drugs A–Z